Hormone therapy

Hormone therapy, also known as hormonal therapy or endocrine therapy, is a treatment modality commonly used in the management of certain types of urological cancers, such as prostate cancer. Hormone therapy works by interfering with the production or action of certain hormones that promote the growth of cancer cells. It is typically used in hormone-sensitive cancers, where the growth and spread of cancer cells are dependent on hormones. 

Indications for Hormone Therapy in Urological Cancer: 

• Prostate Cancer: Hormone therapy is commonly used in the treatment of prostate cancer, which is a hormone-sensitive cancer. It may be used in various settings, including as neoadjuvant or adjuvant therapy before or after surgery, or as palliative treatment for advanced or metastatic prostate cancer. Hormone therapy is used to lower the levels of male hormones, such as testosterone, which can promote the growth of prostate cancer cells. 

Recovery after Hormone Therapy: 

The recovery after hormone therapy depends on the specific treatment and the patient's overall health. Hormone therapy may be used as a long-term treatment for advanced or metastatic prostate cancer, and side effects may vary depending on the duration of treatment. Common side effects of hormone therapy may include hot flashes, decreased sex drive, erectile dysfunction, fatigue, weight gain, and bone loss. Regular monitoring of treatment response, management of side effects, and close follow-up with the healthcare team are important aspects of the recovery process. 

The Department of Uro-Oncology at Sterling Hospitals provides expert hormonal therapy services for urological cancers, including prostate cancer. The experienced oncologists and healthcare professionals work closely with patients to develop personalized treatment plans, monitor treatment response, manage side effects, and provide comprehensive care throughout the treatment journey. State-of-the-art facilities and advanced treatment protocols are available to ensure the best possible outcomes for urological cancer patients.